Clinical Trials List
2022-01-12 - 2027-12-31
Phase II
Not yet recruiting5
ICD-10M32.0
Drug-induced systemic lupus erythematosus
ICD-10M32.10
Systemic lupus erythematosus, organ or system involvement unspecified
ICD-10M32.11
Endocarditis in systemic lupus erythematosus
ICD-10M32.12
Pericarditis in systemic lupus erythematosus
ICD-10M32.13
Lung involvement in systemic lupus erythematosus
ICD-10M32.14
Glomerular disease in systemic lupus erythematosus
ICD-10M32.15
Tubulo-interstitial nephropathy in systemic lupus erythematosus
ICD-10M32.19
Other organ or system involvement in systemic lupus erythematosus
ICD-10M32.8
Other forms of systemic lupus erythematosus
ICD-10M32.9
Systemic lupus erythematosus, unspecified
ICD-9710.0
Systemic lupus erythematosus
-
Trial Applicant
BRISTOL-MYERS SQUIBB (TAIWAN) LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- CHENG-HAN WU 風濕免疫科
- CHIEH-YU SHEN 風濕免疫科
- KO-JEN LI 風濕免疫科
- 呂政勳 風濕免疫科
- 郭佑民 風濕免疫科
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Chang-Youh Tsai Division of Rheumatology
- Yi-Syuan Sun Division of Rheumatology
- Chien-Chih Lai Division of Rheumatology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Yi-Hsing Chen Division of Rheumatology
- 陳彥如 Division of Rheumatology
- 洪維廷 Division of Rheumatology
- WEN-NAN HUANG Division of Rheumatology
- 謝佳偉 Division of Rheumatology
- 廖育婉 Division of Rheumatology
- HSIN-HUA CHEN Division of Rheumatology
- 林靖才 Division of Rheumatology
- 謝祖怡 Division of Rheumatology
- 譚國棟 Division of Rheumatology
- Yi-Ming Chen Division of Rheumatology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- 黃建中 風濕免疫科
- 張詩欣 風濕免疫科
- Po-Hao Huang 風濕免疫科
- Chen Der-Yuan 風濕免疫科
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
10 participants
-
Global
344 participants
